RUPROLIGHT

Light-activatable ruthenium-based anticancer prodrugs

Coordinatore	UNIVERSITEIT LEIDEN    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	1˙418˙400 €
EC contributo	1˙418˙400 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-StG_20111012
Funding Scheme	ERC-SG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-06-01   -   2018-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITEIT LEIDEN  Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2300 RA contact info Titolo: Dr. Nome: Sylvestre Cognome: Bonnet Email: send email Telefono: +31 71 527 4260 Fax: +31 71 527 4671	NL (LEIDEN)	hostInstitution	1˙418˙400.00
2	UNIVERSITEIT LEIDEN  Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2300 RA contact info Titolo: Mr. Nome: Ton Cognome: Brouwer Email: send email Telefono: +31 71 527 3149 Fax: +31 71 527 5269	NL (LEIDEN)	hostInstitution	1˙418˙400.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Chemotherapy is, after surgery, the second most efficient therapy against cancer. However, it has many side effects for cancer patients because anticancer drugs kill cancer cells but also healthy ones. My project aims at synthesizing new metal-containing compounds that 1) are poorly toxic in the dark; 2) can be attached via a light-sensitive bond to liposomes that will carry them into cancer cells; and 3) detach from their carriers and become toxic upon light irradiation, thus killing cancer cells.

These new compounds contain ruthenium, a metal combining photochemical and anticancer properties. I will replace the weakly bound chloride ligands of known cytotoxic ruthenium compounds by strongly bound sulfur ligands. By doing so, the DNA- and protein-binding ability of the ruthenium compounds will be lowered, which will lower their toxicity in the dark. Thioether-lipid conjugates will be used to attach the ruthenium prodrugs to liposomes carriers that are well taken up by cancer cells.

Techniques to irradiate tumors in vivo are nowadays available in the clinics. By shining light onto the ruthenium-enriched cancer cells photochemical cleavage of the Ru-S bond will take place, thus detaching the metal complex from its carrier and allowing it for binding to biological molecules. Thus, the ruthenium prodrug will be transformed inside cancer cells into a highly toxic molecule that will kill the cells. I will study mononuclear compounds and molecules containing several ruthenium centres; visible light activation and near infrared light activation. The final aim is to obtain ruthenium-functionalized liposomes that are poorly toxic in the dark, preferentially go into cancer cells, and become toxic at the place of irradiation, using light that penetrates well into biological tissues.

Because of this unique combination of properties my new light-activatable ruthenium prodrugs will ultimately lead to selective anticancer treatment showing low side effects for cancer patients.'